Pancreatic Cancer Research

ResearcherNational and Kapodistrian University of AthensActive in the last 2 years

Athanasios G. Papavassiliou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5803-4527; OpenAlex author ID A5077783091. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 5 papers

Papers 11

  1. Hungry for fat: Metabolic crosstalk with lipid-rich CAFs fuels pancreatic cancer. First author DOI 10.1016/j.cmet.2024.05.007↗
  2. STAT5: Understanding the Biology of KRASG12D‐Driven Pancreatic Cancer Last author DOI 10.1111/jcmm.70303↗
  3. Retraction: Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Co-author DOI 10.18632/oncotarget.28601↗
  4. Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment. Last author DOI 10.3390/cancers16162876↗
  5. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives. First author DOI 10.3390/ijms25031631↗
  6. Combinatorial Treatment of Tinzaparin and Chemotherapy can Induce a Significant Antitumor Effectin Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-551892/v1↗
  7. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer. Co-author DOI 10.3390/ijms22137053↗
  8. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights. Co-author DOI 10.3390/nu12061543↗
  9. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. Co-author DOI 10.4251/wjgo.v12.i2.173↗
  10. Osteonectin as a screening marker for pancreatic cancer: A prospective study. Last author DOI 10.1177/0300060518772413↗
  11. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Co-author DOI 10.18632/oncotarget.23164↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kostas A. Papavassiliou · 3 shared papers, 2024 · strength 1.10
  2. Christos Adamopoulos · 3 shared papers, 2024 · strength 1.00
  3. Michalis V. Karamouzis · 6 shared papers, 2018–2024 · strength 0.95
  4. Pavlos Papakotoulas · 4 shared papers, 2018–2024 · strength 0.68
  5. Panagiotis Sarantis · 4 shared papers, 2020–2021 · strength 0.52
  6. Evangelos Koustas · 4 shared papers, 2020–2021 · strength 0.52
  7. Chrysovalantou Mihailidou · 2 shared papers, 2018–2024 · strength 0.43
  8. Donatella Delle Cave · 1 shared paper, 2024 · strength 0.36
  9. Nikolaos Vitorakis · 1 shared paper, 2024 · strength 0.28
  10. Stamatios E Theocharis · 2 shared papers, 2021 · strength 0.25
  11. Evangelos S. Felekouras · 2 shared papers, 2021 · strength 0.25
  12. Alexandros Papalampros · 2 shared papers, 2021 · strength 0.25
  13. Dimitriοs Schizas · 2 shared papers, 2021 · strength 0.25
  14. Kalliopi‐Anna Poulia · 1 shared paper, 2020 · strength 0.13
  15. Angeliki Papapanagiotou · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.